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Abstract Placental weight may be regarded as an indirect
marker of hormone exposures during pregnancy. There is
epidemiological evidence that breast cancer mortality in
premenopausal women increases with placental weight in
the most recent pregnancy. We investigated if this associ-
ation differs by tumor characteristics, including expression
of estrogen and progesterone receptors. In a Swedish
population-based cohort, we followed 1,067 women with
premenopausal breast cancer diagnosed from 1992 to 2006.
Using Cox regression models, we estimated hazard ratios
for the association between placental weight and risk of
premenopausal breast cancer mortality. In stratified anal-
yses, we estimated mortality risks in subjects with different
tumor stages, estrogen receptor (ER) or progesterone
receptor (PR) status. Compared with women with placental
weight less than 600 g, women with a placental weight
between 600 and 699 g were at a 50 % increased risk of
mortality, however, not significant change in risk was
observed for women with placental weight C700 g. Mor-
tality risks associated with higher placental weight were
more pronounced among ER- and PR- breast cancer
tumors, where both a placental weight 600–699 g and
C700 g were associated with a more than doubled mor-
tality risks compared with tumors among women with
placental weight less than 600 g. Moreover, stratified
analyses for joint receptor status revealed that a consistent
increased mortality risk by placental weight was only
apparent in women with ER-/PR- breast cancer. The
increased mortality risk in premenopausal breast cancer
associated with higher placental weight was most pro-
nounced among ER- and PR- tumors.
Keywords Breast cancer  Premenopausal  Placental
weight  Estrogen receptor  Progesterone receptor
Introduction
Reproductive factors are well-known risk factors for breast
cancer, but less is known regarding their effect on breast
cancer prognosis. Some pregnancy related factors—such as
parity [7, 20, 39], age at first childbirth [1, 30, 50], and time
between last childbirth and diagnosis of breast cancer [7,
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39] may be used as indicators for different levels of
exposure to pregnancy hormones. Breast cancers, which
are diagnosed shortly after childbirth have poor prognosis
[7, 24, 29, 36, 39, 43, 45, 48], but the impact of other
reproductive factors on survival remain uncertain [1, 7, 29,
30, 36, 45, 50].
Prognostic factors for breast cancer survival include
tumor characteristics—stage and histopathology—and
biological characteristics, such as expression of estrogen
receptor (ER) and progesterone receptor (PR) status [3, 5,
8, 11, 14, 19, 39, 46, 49, 53]. Breast cancer with higher
tumor stages [11, 39, 46, 49], ER-negative [39], PR-neg-
ative [46] or histopathologic type Ductal [11, 19] breast
cancer have poorer survival.
During pregnancy, there is a dramatic increase in levels
of estrogens and other hormones primarily produced by the
placenta [25]. There is a positive association between
placental weight and estrogen levels during pregnancy [18,
25, 37]. In a well-designed prospective study, Mucci et al.
[37] showed that there is a statistically significant positive
association between placental weight and pregnancy
estriol, progesterone, and prolactin levels in maternal
serum samples. Thus, placental weight can be considered
to be an indirect marker of exposure to hormone levels
during pregnancy. During pregnancy and during the years
following pregnancy, there is a transient increase in breast
cancer risk [31]. These ‘‘pregnancy-associated breast can-
cers’’ have a larger frequency of ER- and PR- tumors, and
also a poorer prognosis [17, 38, 43, 47]. In a recent study
[32], we found evidence of a positive association between
increasing placental weight in the most recent pregnancy
and risk of breast cancer mortality. However, due to lack of
information, we were unable to investigate whether the
influence of placental weight on breast cancer mortality
differed by tumor characteristics.
In a Swedish population-based study of more than 1,000
women with premenopausal breast cancer, we had pro-
spectively recorded information on birth characteristics
(including placental weight) and tumor characteristics
(including stage and hormone receptor status). We
hypothesized that the previously observed positive associ-
ation between placental weight in the most recent preg-
nancy and risk of breast cancer mortality vary among
breast cancers with different tumor characteristics.
Materials and methods
Data sources
The cohort was based on information from two Swedish
Regional Quality Registers on Breast Cancer, which was
linked to information from population-based registers, held
by the Swedish National Board of Health and Welfare and
Statistics Sweden. Individual record linkage across these
registers was possible through the unique personal identity
number, assigned to each Swedish resident [33].
The Quality Registers on Breast Cancer is based on
information collected in the six geographically defined
Health Care Regions in Sweden. From 1992 onwards,
information is collected on diagnostic procedures and
treatment, tumor characteristics, including stage at diag-
nosis (tumor size, lymph node involvement, and existence
of distant metastases) and biological characteristics [grade
and hormone (estrogen or progesterone) receptor status] in
all six regions. With regard to capture of incident breast
cancer cases, the Regional Quality Registers are validated
against the national Swedish Cancer Register and have a
completeness exceeding 95 % [6]. For information on
tumor characteristics, the completeness is highest in the
Quality Registers covering the Stockholm-Gotland Region
and the Uppsala-O¨rebro Region in Central Sweden.
The Medical Birth Register includes prospectively col-
lected information during pregnancy, delivery, and the
neonatal period on virtually all births in Sweden since 1973
[13]. Gestational age is based on early second trimester
ultrasound when available; otherwise information about the
time of last menstrual period is used. Placental weight was
recorded between 1982 and 1989.
The Education, Migration, and Causes of Death Regis-
ters provided information about education, and dates of
emigration and death, respectively. The Cause of Death
Register contains information on all deaths on Swedish
residents since 1960. Information is based on death cer-
tificates and contains main and contributory causes of death
coded according to International Classification of Diseases,
7th–10th versions [6].
Study population
Between 1992 and 2006, there were 40,948 women diag-
nosed with breast cancer and registered in the Quality
Registers covering the Stockholm-Gotland Region and the
Uppsala O¨rebro Region in Central Sweden. At the time of
breast cancer diagnosis, women were asked whether they
were premenopausal or postmenopausal. Of in total 8,508
women with premenopausal breast cancer, 7,399 were
excluded because they were nulliparous or data on pla-
cental weight at their last pregnancy before breast cancer
diagnosis were not recorded (placental weight was only
recorded in births between 1982 and 1989), We excluded
eight subjects due to missing information on gestational
age and 34 subjects with implausible placental weights.
Although breast cancer was recorded as premenopausal or
postmenopausal, we preferred to also exclude 24 subjects
with recorded premenopausal breast cancer whose age at
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diagnosis was more than 55 years. In total, the study cohort
included 1,067 women with premenopausal breast cancer
and information about placental weight in their last preg-
nancy before breast cancer diagnosis. We followed the
study subjects from the date of breast cancer diagnosis until
emigration, death or until December 31st, 2008, whichever
occurred first.
Statistical analysis
We used Cox regression models to estimate hazard ratios
(HR) with 95 % confidence intervals (CI) as a measure of
the association between placental weight and risk of pre-
menopausal breast cancer mortality. Follow-up time was
the underlying time scale. Placental weight was considered
both as a continuous and a categorized variable (\600,
600–699, and C700 g). The cut offs were chosen to ensure
that enough number of subjects and events were present in
each category. The models were adjusted for gestational
age (B36, 37–38, 39–41, and C42 weeks), parity (1, 2, 3,
and C4), age at diagnosis of breast cancer (\30, 30–34,
35–39, 40–44, 45–49, and 50–54 years), and education
level (less than high school, high school, and more than
high school).
To check for interaction effects, we added interaction
terms of placental weight (categorical variable) and stage
of tumor, ER or PR status (categorical variables) and his-
tology of tumor into the full models. We performed strat-
ified analyses to estimate the risks of breast cancer
mortality in subjects with different tumor stages (stage 0–1,
stage 2, or stage 3–4), ER status (ER?, ER-) and PR status
(PR?, PR-), and histology of tumors (Ductal, Lobular,
Other). We also performed the stratified analyses for joint
receptor status (ER?PR?, ER?PR-, ER-PR?, ER-PR-).
The assumption of proportionality was verified for all of
the analyses by including time-by covariate interaction in
the model and testing the statistical significance. All
analyses were performed using the SAS software version
9.2 (SAS Institute, Cary, NC, USA).
Results
Table 1 shows characteristics of the cohort and crude
(unadjusted) mortality risks. Compared with women with
placental weight less than 600 g, women with placental
weight 600–699 g in the most recent pregnancy had
*50 % higher mortality risk after diagnosis of premeno-
pausal breast cancer. In contrast, no increased mortality
risk could be detected for women with a placental weight
of 700 g or more. Low age at diagnosis of breast cancer
and short time difference (\10 years) between last child-
birth and diagnosis of breast cancer were associated with
Table 1 Characteristic of 1067 parous women with premenopausal
breast cancer diagnosed 1992–2006, and crude hazard ratios (HR) for
mortality
Total Subject Event Crude HR (95 %
CI)1,067 180
Offsprings charactistics (last pregnancy)
Placental weight (g)
\600 458 70 Reference
600–699 322 69 1.49 (1.07–2.08)
C700 287 41 0.90 (0.61–1.32)
Continuous, 50 g 1067 180 1,00 (0.94–1.05)
Mean (SD) 622.27 (123.5)
Median (range) 610 (220–980)
Gestational age (weeks)
B36 66 10 0.87 (0.43–1.75)
37–38 194 35 Reference
39–41 745 120 0.97 (0.67–1.42)
C42 62 15 1.35 (0.74–2.47)
Continuous (weeks) 1,067 180 1.09 (0.87–1.37)
Mean (SD) 39.28 (2.0)
Median (range) 40.00 (23–44)
The subjects characteristics
Parity
1 158 36 Reference
2 559 87 0.73 (0.49–1.07)
3 272 44 0.67 (0.43–1.04)
C4 78 13 0.58 (0.31–1.10)
Continuous 1,067 180 0.84 (0.70–1.01)
Mean (SD) 2.27 (0.9)
Median (range) 2.00 (1–7)
Age at diagnosis (years)
\30 5 2 1.74 (0.42–7.14)
30–34 14 9 4.07 (2.02–8.20)
35–39 91 34 1.96 (1.29–2.99)
40–44 265 60 1.35 (0.95–1.93)
45–49 458 62 Reference
50–54 234 13 0.54 (0.30–0.99)
Continuous (year) 1,067 180 0.70 (0.61–0.80)
Mean (SD) 45.61 (4.6)
Median (range) 46.00 (28–54)
Age at first childbirth (years)
B19 51 8 1.47 (0.64–3.40)
20–24 308 47 1.27 (0.74–2.20)
25–29 416 60 1.03 (0.61–1.76)
30–34 208 47 1.37 (0.80–2.37)
C35 84 18 Reference
Continuous, year 1,067 180 0.97 (0.84–1.12)
Mean (SD) 26.81 (4.8)
Median (range) 26.00 (15–43)
Education level
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increased risks of premenopausal breast cancer mortality,
and mortality risk increased with decreasing educational
level. Gestational age, parity, and age at first childbirth did
not influence premenopausal breast cancer mortality. As
expected, breast cancer mortality increased with stage of
breast cancer. Compared with women with ER? or PR?
tumor, women with ER- or PR- tumors had higher mor-
tality, respectively,
Adjusting for gestational age, parity, age at diagnosis,
and education level did not notably change the overall
association between placental weight and breast cancer
mortality. In the adjusted analysis, women with a placental
weight between 600 and 699 g faced a 50 % increased risk
of mortality (HR 1.51; 95 % CI 1.07–2.12) compared with
women with a low placental weight (\600 g), However, a
placental weight of at least 700 g was not associated with
an increased risk of breast cancer mortality (HR 0.88; 95 %
CI 0.60–1.30, data not shown in Table).
In a subsequent step, analyses of placental weight and
breast cancer mortality were stratified by tumor charac-
teristics (Table 2). First, analyses were stratified by tumor
stage. There was no statistically significant interaction
between stage of tumor and placental weight with respect
to breast cancer mortality (p = 0.80). In the crude analy-
ses, there were no significant associations between pla-
cental weight and breast cancer mortality. In the adjusted
analysis of premenopausal breast cancer stages 3–4,
women with a placental weight between 600 and 699 g and
at least 700 g had a four- and a threefold increased mor-
tality risk compared with women with a placental weight of
less than 600 g. The reasons for the discrepancy between
crude and adjusted risk estimates of placental weight and
stage 3–4 breast cancer mortality were primarily effects of
adjusting for parity and educational level (data not shown).
There were statistically significant interactions between
placental weight and ER and PR with respect to mortality
risk (p \ 0.01 and p \ 0.0001, respectively). Analyses
stratified by ER status showed that the higher mortality risk
associated with placental weight among ER? tumors was
restricted to placental weight 600–699 g (HR 1.87; 95 %
CI 1.13-3.11), while among ER- tumors, both placental
weight 600-699 g and C700 g were associated with than a
doubled mortality risk compared with tumors among
women with placental weight less than 600 g. Similarly, an
increased mortality risk among PR? tumors was (if any-
thing) only observed for women with a placental weight
between 600 and 699 g, who had a 60 % increase in
mortality, which was of borderline significance. Among
women with PR- tumors, both placental weight 600–699 g
and C700 g were associated with more than tripled mor-
tality risks compared with women with a placental weight
less than 600 g.
In analyses stratified for joint receptor status, a consistent
increase in breast cancer mortality with increasing placental
weight was found only among women with ER-/PR- tumors
(Table 3).
Discussion
The results of the present study indicate that the association
between increasing placental weight in the most recent
pregnancy and premenopausal breast cancer mortality
Table 1 continued
Total Subject Event Crude HR (95 %
CI)1,067 180
Less than high
school
127 33 Reference
High school 506 92 0.79 (0.53–1.17)
More than high
school
432 55 0.46 (0.30–0.71)
Unknown 2 0 0.00
Time difference between last pregnancy and date of diagnosis, years
\10 211 82 2.07 (1.52–2.81)
C10 856 98 Reference
Continuous, year 1067 180 0.92 (0.88–0.95)
Mean (SD) 14.33 (4.8)
Median (range) 14.30
(2.5–26.8)
Tumor characteristics
Stage of tumor
Stage 0–1 574 51 Reference
Stage 2 304 58 2.02 (1.39–2.95)
Stage 3–4 44 27 9.58 (6.00–15.28)
Unknown 145 44 2.30 (1.53–3.46)
ER status
Positive 698 79 Reference
Negative 196 54 2.16 (1.00–3.05)
Unknown 173 180 1.76 (1.23–2.53)
PR status
Positive 674 77 Reference
Negative 219 56 2.13 (1.51–3.00)
Unknown 174 47 1.77 (1.23–2.54)
ER/PR status
ER?/PR? 621 64 Reference
ER?/PR- 71 13 1.73 (0.95–3.15)
ER-/PR? 48 11 1.79 (0.94–3.40)
ER-/PR- 148 43 2.57 (1.74–3.78)
Unknown 179 49 1.95 (1.43–2.83)
Histotype of tumor
Ductal 718 112 Reference
Lobular 129 21 0.96 (0.61–1.54)
Other 220 47 0.93 (0.66–1.32)
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Table 2 Crude and adjusted hazard ratio (HR) and 95 % confidence interval (CI) for mortality associated with placental weight and tumor
characteristics among women with premenopausal breast cancer who had pregnancy during 1982–1989
Subject Event Crude HR(95 % CI) Adjusted HR(95 % CI)a
Tumor characteristics
Stage 0–1
Placental weight (g)
\600 258 18 Reference Reference
600–699 170 20 1.74 (0.92–3.28) 1.57 (0.82–3.00)
C700 146 13 1.25 (0.62–2.55) 1.17 (0.57–2.42)
Continuous, 50 g 574 51 0.98 (0.88–1.10) 0.98 (0.87–1.09)
Stage 2
Placental weight (g)
\600 117 22 Reference Reference
600–699 97 27 1.64 (0.93–2.89) 1.70 (0.91–3.17)
C700 90 9 0.47 (0.22–1.03) 0.47 (0.21–1.07)
Continuous, 50 g 304 58 0.91 (0.82–1.01) 0.88 (0.78–0.98)
Stage 3–4
Placental weight (g)
\600 16 9 Reference Reference
600–699 12 9 1.67 (0.66–4.25) 4.28 (1.23–14.97)
C700 16 9 1.29 (0.51–3.30) 3.40 (0.96–12.05)
Continuous, 50 g 44 27 1.06 (0.92–1.23) 1.10 (0.94–1.28)
Biological characteristics
ER?
Placental weight (g)
\600 303 32 Reference Reference
600–699 217 35 1.63 (1.01–2.64) 1.87 (1.13–3.11)
C700 178 12 0.58 (0.30–1.12) 0.59 (0.30–1.14)
Continuous, 50 g 698 79 0.97 (0.88–1.06) 0.96 (0.88–1.05)
ER-
Placental weight (g)
\600 81 14 Reference Reference
600–699 57 20 2.23 (1.12–4.41) 2.51 (1.20–5.25)
C700 58 20 2.29 (1.16–4.53) 2.41 (1.17–4.99)
Continuous, 50 g 196 54 1.12 (1.01–1.24) 1.11 (0.99–1.23)
PR?
Placental weight (g)
\600 295 33 Reference Reference
600–699 204 33 1.53 (0.94–2.48) 1.62 (0.99–2.68)
C700 175 11 0.51 (0.26–1.00) 0.47 (0.24–0.94)
Continuous, 50 g 674 77 0.95 (0.87–1.04) 0.93 (0.85–1.02)
PR-
Placental weight (g)
\600 86 11 Reference Reference
600–699 72 24 2.92 (1.43–5.96) 3.22 (1.47–7.04)
C700 61 21 3.03 (1.46–6.29) 3.56 (1.58–8.04)
Continuous, 50 g 219 56 1.17 (1.04–1.30) 1.18 (1.05–1.32)
Histopathology
Ductal
Placental weight (g)
\600 307 39 Reference Reference
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differs by tumor receptor status. A positive association
between placental weight and breast cancer mortality was
more pronounced among ER- and PR- tumors than among
ER? and PR? tumors. These results confirm and extend on
our previous findings that placental weight influences the
risk of premenopausal breast cancer mortality [32]. How-
ever, we did not find a dose–response association between
placental weight and overall risk of premenopausal breast
cancer mortality.
Analyses in relation to joint receptor status revealed that
a consistent increase in breast cancer mortality with
increasing placental weight was restricted to patients with
ER-/PR- tumors. It has been suggested that breast cancer
tumors should be categorized based on the status of both
ERs and PRs, rather than categorizing ER and PR sepa-
rately [44]. ER-/PR- tumors are more frequent in pre-
menopausal breast cancer, while ER?/PR? tumors occur
more frequently in postmenopausal breast cancer [3, 44,
54, 56]. Moreover, ER- and PR- tumors have higher stage
[3, 44, 54], higher proliferation rate [41, 51, 54] and higher
S-phase fraction [41, 55]. The distribution of receptors is
more age dependent [2–4, 9, 12, 16, 19, 57] than related to
menopausal status. ER- breast cancer rates increase with
age during premenopausal period, and flatten to a constant
level after 50 years, while the rate of ER? tumors increases
with older age, with the greatest risk occurring after
70 years [4, 57]. A significantly higher frequency of ER-/
PR- tumors has been reported among cases with pregnancy
related breast cancers [38, 43]. This pattern suggests that
premenopausal hormonal exposures have greater impact on
receptor negative tumors than on receptor positive tumors.
However, the biological mechanism underlying the
observed increased risk of breast cancer mortality among
patients with ER-/PR- tumors and higher placental weight
is not clear.
This study showed that the premenopausal breast cancer
mortality in women with ER- and PR- tumors is higher
compared with women with ER? and PR? tumors, which is
consistent with the results of previous studies [3, 7, 11, 14,
15, 26, 39]. In a large cohort study, Dunnwald et al. [15]
found that compared with women with ER?/PR? tumors,
women with ER?/PR-, ER-/PR?, or ER-/PR- tumors
experienced higher risks of premenopausal breast cancer
mortality. This risk increase was largely independent of
demographic and clinical tumor characteristics, and the
highest risk was observed in patients with ER-/PR-
tumors. While studying ER?/PR- and ER-/PR? tumors
could be problematic due to the low frequency of these
types of tumors [3, 22, 44, 56], it has been suggested that
the presence of estrogen and ERs is necessary for synthesis
of PRs. Thus, identifying a tumor with receptor status as
ER-/PR? could be a false diagnosis due to laboratory
mistake [27]. Receptor positive tumors could also change
to receptor negative status over time [23].
Consistent with our results, Lukanova et al. [34] found
an increased risk of breast cancer associated with higher
concentration of estrogen during first trimester of preg-
nancy and higher proportion of receptor negative tumors
among women diagnosed before age 40. The authors
speculate that there is a direct association between con-
centration of estrogen and ER-negative tumors, which is
supported by an animal study, showing that breast cancer
tumors require estrogen for their formation and progres-
sion in spite of negativity of ER [21]. However, Peck
Table 2 continued
Subject Event Crude HR(95 % CI) Adjusted HR(95 % CI)a
600–699 222 48 1.73 (1.14–2.65) 1.90 (1.23–2.94)
C700 189 25 0.95 (0.57–1.56) 0.91 (0.54–1.53)
Continuous, 50 g 718 112 1.01 (0.94–1.09) 0.99 (0.92–1.07)
Lobular
Placental weight (g)
\600 53 7 Reference Reference
600–699 35 9 2.57 (0.95–6.94) 4.46 (1.26–15.84)
C700 41 5 0.93 (0.29–2.92) 0.73 (0.19–2.77)
Continuous, 50 g 129 21 0.99 (0.84–1.16) 0.93 (0.80–1.09)
Other
Placental weight (g)
\600 98 24 Reference Reference
600–699 65 12 0.80 (0.40–1.61) 0.84 (0.40–1.78)
C700 57 11 0.81 (0.40–1.65) 0.85 (0.40–1.81)
Continuous, 50 g 220 47 0.96 (0.85–1.09) 0.96 (0.85–1.10)
a Adjusted for gestational age, parity, age at diagnosis, and education level
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et al. [42] did not find a clear association between estro-
gen levels in third trimester of pregnancy and risk of
breast cancer. Moreover, a recent large cohort study did
not find any association between placental weight and
breast cancer risk [40]. Taken together, the results of these
studies indicate that estrogens may be of importance
in proliferation of breast cells during early stage of
pregnancy.
In this study, we found no association between parity
and breast cancer mortality, collaborating findings of some
previous studies [1, 29, 30, 45, 50]. However, other studies
have reported lower [20, 35] or higher breast cancer mor-
tality [10, 28, 39, 43] associated with increasing parity.
These discrepant results could be due to differences in
study designs. For example, pre- and postmenopausal
breast cancers have different risk profiles with respect to
mortality, and most studies do not investigate pre- and
postmenopausal breast cancer separately [10, 20, 28, 35,
39, 43]. The observed association between placental weight
and lobular premenopausal breast cancer is based on few
events and could be chance finding.
Strengths of this study include the population-based
design including virtually all women in Central Sweden
diagnosed with breast cancer during the study period. In
addition, recall bias was not an issue by the use of pro-
spectively recorded information about pregnancy charac-
teristics and detailed information on tumor characteristics
retrieved from separate data sources. The source population
for Regional Clinical Quality Registers for Breast Cancer
in the Uppsala/O¨rebro and Stockholm/Gotland regions is
about 4 million (43 % of the Swedish population) living in
both urban and rural areas, and is representative of Swedish
population as a whole. The completeness of the informa-
tion on tumor characteristics is among the highest in the
Quality Registers covering these regions.
In contrast to our previous study [32], we did not find a
dose–response relationship between placental weight and
overall risk of premenopausal breast cancer mortality. In
our previous study, stratified analyses revealed that this
dose–response relationship was only apparent in preg-
nancy-associated breast cancer—women diagnosed with
breast cancer during pregnancy or up to 2 years after
Table 3 Crude and adjusted Hazard Ratio (HR) and 95 % confidence
interval (CI) for mortality associated with placental weight and joint
status of estrogen receptor (ER) and progesterone receptor (PR)
among women with premenopausal breast cancer who had pregnancy
during 1982–1989
Subject Event Crude HR(95 % CI) Adjusted HR(95 % CI)a
ER? PR?
Placental weight (g)
\600 268 28 Reference Reference
600–699 192 27 1.43 (0.84–2.44) 1.60 (0.92–2.80)
C700 161 9 0.48 (0.23–1.03) 0.44 (0.21–0.95)
Continuous, 50 g 621 64 0.94 (0.85–1.05) 0.92 (0.83–1.03)
ER? PR-
Placental weight (g)
\600 30 2 Reference Reference
600–699 24 8 5.42 (1.15–25.55) 13.25 (1.16–151.29)
C700 17 3 2.28 (0.38–13.68) 5.43 (0.48–61.48)
Continuous, 50 g 71 13 1.17 (0.91–1.50) 1.20 (0.91–1.56)
ER- PR?
Placental weight (g)
\600 25 5 Reference Reference
600–699 9 4 2.32 (0.62–8.68) 9.66 (1.27–73.34)
C700 14 2 0.73 (0.14–3.75) 0.53 (0.09–3.18)
Continuous, 50 g 48 11 0.96 (0.48–1.89) 0.96 (0.76–1.21)
ER- PR-
Placental weight (g)
\600 56 9 Reference Reference
600–699 48 16 2.29 (1.01–5.18) 2.69 (1.12–6.47)
C700 44 18 3.06 (1.37–6.82) 3.86 (1.56–9.57)
Continuous, 50 g 148 43 1.15 (1.02–1.30) 1.17 (1.03–1.32)
a Adjusted for gestational age, parity, age at diagnosis, and education level
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childbirth [32]. In the present investigation, we were
unable to study associations between placental weight and
mortality in women with pregnancy-associated breast
cancer, since information on placental weight was not
collected after 1989 and the Quality Registers of breast
cancer started to collect information on tumor character-
istics in 1992. Thus, our study design prevented us to study
the association between placental weight and mortality in
pregnancy-associated breast cancer, i.e., the time window
when exposure to pregnancy hormones may be most
important for breast cancer survival. Other limitations
include small number of events (deaths), which limited our
statistical power. For this reason, we had to categorize
tumor stage only in three groups instead of the standard
classification [52].
In conclusion, our study supports the hypothesis that
hormone levels during pregnancy might influence pre-
menopausal breast cancer mortality, and that this associa-
tion differs by tumor receptor status. The increased
mortality risk associated with higher placental weight
observed in ER- and PR- tumors suggests that premeno-
pausal hormonal exposures might have greater impact on
these tumors.
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